Rani Therapeutics Holdings, Inc. RANI
Regular-session close
After hours · Nov 19, 6:12 PM ET
- YTD
- -56.99%
- 1 year
- -66.82%
5D +0.0719 (+13.48%)
- Market cap
- 67.05M
- EPS (ttm)
- -0.07
- Shares out
- 33.31M
- Forward P/E
- -1.41
- YTD return
- -56.99%
- 1-year return
- -66.82%
- 50-day average
- 2.15
- 200-day average
- 3.43
- Volume
- 535.31K
- Avg volume
- 553.26K
- Open
- 0.65
- Previous close
- 0.6481
- Day's range
- 0.56 – 0.6503
- 52-week range
- 0.502 – 1.82
- Beta
- 0.11
- Price target
- 11.50 (+1880.7%)
Key statistics
- Enterprise value
- 75.89M
- Price / book
- 2.87
- Free cash flow
- -22.84M
- Total cash
- 30.90M
- Total debt
- 35.25M
- Return on equity
- -225.35%
- Short % of float
- 7.72%
Fundamental scorecard
9 of 25 checks passed on RANI’s reported financials
9of 25 checks passed
- Value 2 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.22 | -0.24 | -0.02 | -9.09% |
| Aug 6, 2024 | Jun 1, 2024 | -0.29 | — | — | — |
| Aug 6, 2024 | Jun 1, 2024 | -0.29 | -0.26 | +0.03 | +10.34% |
| May 6, 2024 | Mar 1, 2024 | -0.23 | — | — | — |
| May 6, 2024 | Mar 1, 2024 | -0.23 | -0.29 | -0.06 | -26.09% |
| Mar 20, 2024 | Dec 1, 2023 | -0.31 | -0.27 | +0.04 | +12.90% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 16, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 2, 2024 | Oppenheimer | init | — | Outperform |
| Jun 25, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 14, 2024 | Maxim Group | init | — | Buy |
About Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ranitherapeutics.com
News
Rani Therapeutics Hldgs Q3 EPS $(0.04) Beats $(0.05) Estimate, Sales $1.707M Beat $1.280M Estimate
Rani Therapeutics Reports Third Quarter 2026 Financial Results; Provides Corporate Update
Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances
Rani Therapeutics to Participate in the Chardan Healthcare Conference
Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)
Rani Therapeutics to Participate in Upcoming September Conferences
Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update
Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Your note
Sign in to keep a note on RANI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BUTEL JEAN LUC | Director | Purchase | Nov 16, 2023 | 50,500 |
| GROEN ERIC | General Counsel | Stock Award(Grant) | Mar 26, 2023 | 163,216 |
| HASHIM MIR | Officer | Stock Award(Grant) | Mar 26, 2023 | 273,265 |
| IMRAN TALAT | Chief Executive Officer | Purchase | Dec 8, 2024 | 494,751 |
| MCKINLEY KATE | Officer | Purchase | Dec 12, 2024 | 17,960 |
| NANAVATY MAULIK | Director | Purchase | Nov 15, 2023 | 11,517 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 7.73% | 2,574,000 | 3.66M | Sep 29, 2024 |
| Vanguard Group Inc | 2.13% | 709,828 | 1.01M | Sep 29, 2024 |
| Nan Fung Group Holdings Limited | 1.48% | 493,584 | 700.89K | Sep 29, 2024 |
| Alphabet Inc. | 1.35% | 448,492 | 636.86K | Sep 29, 2024 |
| United Services Automobile Association | 0.91% | 302,743 | 429.89K | Sep 29, 2024 |
| Stifel Financial Corporation | 0.81% | 269,768 | 383.07K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.56% | 518,702 | 736.56K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.52% | 172,976 | 245.63K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.27% | 88,844 | 126.16K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.21% | 71,500 | 101.53K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 26,167 | 37.16K | Oct 30, 2024 |
| Northern Small Cap Core Fund | 0.07% | 23,700 | 33.65K | Sep 29, 2024 |
